Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSHR | P23945 | 15/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601275 | 0.89 | FSHR (0.57) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL3398323 | 0.87 | FSHR (0.64) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL3393370 | 0.86 | FSHR (0.58) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL3391468 | 0.85 | FSHR (0.65) | FSHRTSHRHPGDMEN1ADRB2 | |
| SCHEMBL3393820 | 0.85 | FSHR (0.61) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL4600825 | 0.84 | FSHR (0.68) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL3398312 | 0.84 | FSHR (0.55) | FSHRTSHRHPGDMEN1ADRB2 | |
| SCHEMBL4601274 | 0.83 | FSHR (0.56) | FSHRTSHRHPGDNPSR1 | |
| SCHEMBL3433337 | 0.82 | FSHR (0.68) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL3393050 | 0.82 | FSHR (0.67) | FSHRTSHRMEN1ADRB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674909-B2 | Biphenyl-4-carboxylic acid {1-acetyl-4-[4-(2-dimethylammo-ethoxy-phenyl]-2,2,4-trimethyl-1,2,3,4-tetrahydro-quinolin-6-yl}-amide; fertility regulation; follicle stimulating hormone (FSH) | N.V. ORGANON (NL) | 2010-03-09 | — | — | US | disclosed |
| EP-1578727-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS FSH RECEPTOR MODULATORS | ORGANON NV (NL) | 2008-04-16 | — | — | EP | disclosed |
| US-20060167047-A1 | Tetrahydorquinoline derivatives and their use as fsh receptor modulators | MERCK SHARP & DOHME B.V. (NL) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167047-A1 | Tetrahydorquinoline derivatives and their use as fsh receptor modulators | FSHR, GNRHR, LHCGR | FSHR 1/4885TSHR 18/4885CYP1A2 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.